Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.81
+0.14 (2.10%)
At close: May 8, 2026, 4:00 PM EDT
6.75
-0.06 (-0.88%)
After-hours: May 8, 2026, 6:49 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.96 billion as of May 8, 2026. Its market cap has increased by 424.33% in one year.
Market Cap
1.96B
Enterprise Value
1.75B
1-Year Change
424.33%
Ranking
Category
Stock Price
$6.81
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.96B, an increase of 183.42%. That is a compound annual growth rate of 20.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 8, 2026 | 1.96B | 29.89% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Inhibrx Biosciences | 2.07B |
| Zymeworks | 2.04B |
| Trevi Therapeutics | 2.02B |
| Tyra Biosciences | 2.01B |
| Capricor Therapeutics | 1.99B |
| Ascentage Pharma Group International | 1.99B |
| Nanobiotix | 1.98B |
| Pharvaris | 1.97B |